See Why Is Stifel Analyst 'Perplexed' After ChemoCentryx Q4 Earnings

  • Stifel has reiterated a Buy rating and $85 price target on ChemoCentryx Inc CCXI following the Q4 results.
  • Analyst Dae Gon Ha says he is "perplexed" by the pronounced weakness on what he views as a positive-launch quarter. 
  • Ha tells investors in a research note that 127 patient start forms and 71% conversion rate strike is positive. In contrast, management's January 2022 commentary was perceived as cautious/negative by some $1 million in Q4 product sales beat consensus estimates. 
  • The analyst is more optimistic today on Tavneos' outlook, he adds.
  • ChemoCentryx reported a Q4 EPS loss of $(0.58) which missed the analyst consensus estimate of $(0.50). 
  • The Company reported quarterly sales of $2.31 million, below the consensus estimate of $11.62 million, down 47% Y/Y.
  • The Company held cash, cash equivalents of approximately $362.3 million. ChemoCentryx reported Tavneos US sales of $1.0 million.
  • Price Action: CCXI shares are down 21.20% at $23.22 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechEarningsNewsHealth CareReiterationSmall CapAnalyst RatingsMoversGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!